T

argeted cancer therapy developer Loxo Oncology (LOXO) is licensing its two lead drugs to the German pharma giant Bayer, the companies announced Tuesday.

Under the agreement, Loxo will receive $400 million upfront from Bayer in exchange for global development and marketing rights to larotrectinib and LOXO-195. Both drugs target a rare genetic flaw known as TRK gene fusion found across a range of different cancer types.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy